Komori
Revision of earnings forecasts4506Sumitomo Pharma Co.,Ltd.Pharmaceuticals

Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [IFRS] (Consolidated)

The consolidated earnings forecast for the cumulative second quarter of the fiscal year ending March 2027 was disclosed for the first time. The full-year forecast remains unchanged from the initial forecast.

Worth reading
70In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending March 2027 · Cumulative second quarter (interim period)Previous forecast published Announced on 13 May 2026
Net Sales—→251,000million
—
Operating profit—→30,000million
—
Profit attributable to owners of the parent—→26,000million
—
Net income per share—→58.8yen and sen
—

The bar length represents the relative magnitude of change, based on the item that changed the most in this document.

Reason for the revision

Based on the first-quarter consolidated results and the outlook for the second quarter, the consolidated earnings forecast for the cumulative second quarter (interim period) is being disclosed.

Previous-period resultsRevenue: ¥227,122 million; core operating profit: ¥96,084 million; operating profit: ¥96,157 million; interim profit attributable to owners of the parent: ¥98,860 million; basic interim earnings per share: ¥248.84
Dividend forecast revisionThere is no revision to the dividend forecast. The dividend forecast for the fiscal year ending March 2027 has not yet been determined.
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net SalesNot disclosed → ¥251,000 million
Operating profitNot disclosed → ¥30,000 million
Profit attributable to owners of the parentNot disclosed → ¥26,000 million
Net income per shareNot disclosed → 58.8 yen and sen
Fiscal Period CoveredFiscal year ending March 2027
Period CoveredCumulative second quarter (interim period)
Publication date of previous forecastAnnounced on 13 May 2026
Previous-period resultsRevenue: ¥227,122 million; core operating profit: ¥96,084 million; operating profit: ¥96,157 million; interim profit attributable to owners of the parent: ¥98,860 million; basic interim earnings per share: ¥248.84
Reason for the revisionBased on the first-quarter consolidated results and the outlook for the second quarter, the consolidated earnings forecast for the cumulative second quarter (interim period) is being disclosed.
Dividend forecast revisionThere is no revision to the dividend forecast. The dividend forecast for the fiscal year ending March 2027 has not yet been determined.
Consolidated / non-consolidatedConsolidated
Items this document does not state (2)
Ordinary incomeDetails and amount of extraordinary loss

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This was based on the first-quarter consolidated results and the outlook for the second quarter. The full-year forecast has not been changed from the initial forecast.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [IFRS] (Consolidated) | Sumitomo Pharma Co.,Ltd. (4506) timely disclosure | Komori